GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corium International Inc (NAS:CORI) » Definitions » Change In Other Working Capital

Corium International (Corium International) Change In Other Working Capital : $-0.14 Mil (TTM As of Jun. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Corium International Change In Other Working Capital?

Corium International's Change In Other Working Capital for the quarter that ended in Jun. 2018 was $-0.08 Mil. It means Corium International's Other Working Capital declined by $0.08 Mil from Mar. 2018 to Jun. 2018 .

Corium International's Change In Other Working Capital for the fiscal year that ended in Sep. 2017 was $-0.12 Mil. It means Corium International's Other Working Capital declined by $0.12 Mil from Sep. 2016 to Sep. 2017 .


Corium International Change In Other Working Capital Historical Data

The historical data trend for Corium International's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corium International Change In Other Working Capital Chart

Corium International Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17
Change In Other Working Capital
Get a 7-Day Free Trial 0.15 -3.12 -0.89 -0.45 -0.12

Corium International Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 0.46 -0.24 -0.28 -0.08

Corium International Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corium International Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Corium International's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Corium International (Corium International) Business Description

Traded in Other Exchanges
N/A
Address
Corium International Inc is a commercial-stage biopharmaceutical company which is focused on the development, manufacture, and commercialization of specialty pharmaceutical products. The company has multiple proprietary programs in preclinical and clinical development focusing primarily on the treatment of neurological disorders. It has few proprietary transdermal platforms such as Corplex for small molecules and MicroCor which is a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides, and proteins. The company's products include Clonidine TDS, Fentanyl TDS, and Crest Whitestrips.
Executives
Essex Woodlands Health Ventures Fund Vii Lp 10 percent owner 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Robert S Breuil officer: Chief Financial Officer 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Ronald W Eastman director, 10 percent owner 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Paul Goddard director ADOLOR CORPORATION, 700 PENNSYLVANIA DR., EXTON PA 19341
David Greenwood director 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Ivan P. Gergel director C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO CA 94158
Peter D Staple director, officer: President & CEO 863 C MITTEN ROAD, BURLINGAME CA 94010
Joseph J. Sarret officer: Chief Business Officer C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

Corium International (Corium International) Headlines

From GuruFocus

Insiders Roundup: Walmart, Eli Lilly

By Tiziano Frateschi Tiziano Frateschi 11-30-2018